Oncology & Cancer

CheckMate 743 shows that dual immunotherapy, nivolumab + ipilimumab

The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research ...

page 1 from 3